Senti Biosciences, Inc.
Engineered living cells with synthetic gene circuits that sense disease states and produce therapeutic responses
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2016
- Latest Form D
- $39.4M, Feb 2018
- Total capital
- $42.4M
- Federal grants
- $450K
- 2 awards · 2017–2018
- Rank in peer group#302 of 502
- Private capital raised
- $39.4M
- 1 Form D · last Feb 2018
- 104 months since last filing
- Federal contracts
- $2.6M
- 2 awards · Defense, Health and Human S
- Rank in Biotech#122 of 4373
- Granted patents
- 6
- 34 pending · first 2021
- Rank in peer group#13 of 502
Capital timeline
Latest events
- Federal contractHealth and Human S · Topic 414 : Synthetic Biology Gene Circuits For Cancer Therapy$2M
- Federal grantHealth and Human S · Phase I · Engineering Cell Therapies to Treat Inflammatory Bowel Disease (IBD)$225K
- Private capital raisedForm D · SEC · 1st filing$39.4M
- Federal grantNSF · Phase I · SBIR Phase I: An Engineering Platform for Adaptive Medicines$225K
- Federal contractDefense · Igf::ot::igf - Biological Technologies Office Study - Programmable Therapeutic Cell Circuit Platforms$583K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
18months
from Senti Biosciences, Inc.’s first federal award to its first private round.
- First federal award · Sep 2016
- Defense · $583K
- First Form D · Feb 2018
- $39.4M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#13 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Philip LeeResearcherExecutive OfficerLinked by $225K in grants as PI
- Alex KolicichDirectorNamed in SEC Form D filings
- Brenda CooperstoneDirectorNamed in SEC Form D filings
- Donald TangDirectorNamed in SEC Form D filings
- Ed MathersDirectorNamed in SEC Form D filings
- Edward MathersDirectorNamed in SEC Form D filings
Show all 11 people
- Fran SchulzDirectorNamed in SEC Form D filings
- James CollinsDirectorNamed in SEC Form D filings
- Kanya RajangamExecutive OfficerNamed in SEC Form D filings
- Timothy LuExecutive Officer, DirectorNamed in SEC Form D filings
- Yvonne LiExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingChimeric Receptors And Methods Of Use ThereofUSPTOApplication 19573945
- PendingProtein Payload ReleaseUSPTOApplication 19551508
- PendingMethods And Compositions For Cell-surface Co-localization Of Chimeric ProteinsUSPTOApplication 19126923
Show all 40 patent records
- Chimeric Receptors And Methods Of Use ThereofAug 13, 2026 · Application 19573945Pending
- Protein Payload ReleaseAug 6, 2026 · Application 19551508Pending
- Methods And Compositions For Cell-surface Co-localization Of Chimeric ProteinsJun 18, 2026 · Application 19126923Pending
- Protein Payload ReleaseJun 16, 2026 · US 12,653,839Granted
- Armed Chimeric Receptors And Methods Of Use ThereofMay 28, 2026 · Application 19172467Pending
- Chimeric Receptors And Methods Of Use ThereofApr 28, 2026 · US 12,611,458Granted
- ERT2 Mutants, Inducible Cell Death Systems, And Uses ThereofJan 22, 2026 · Application 19288667Pending
- Inhibitory Chimeric Receptor ArchitecturesNov 6, 2025 · Application 19036956Pending
- Macrophage-specific Promoters And Uses ThereofSep 25, 2025 · Application 19228187Pending
- Cell-type Specific Regulatory Elements For PhotoreceptorsJul 10, 2025 · Application 19093913Pending
- Multicistronic Chimeric Protein Expression SystemsFeb 6, 2025 · Application 18922220Pending
- Antigen-binding Domains And Methods Of Use ThereofJan 30, 2025 · Application 18920680Pending
- Cytokine-immunoreceptor Fusion Proteins And Uses ThereofJan 9, 2025 · Application 18777176Pending
- Activation Responsive Promoters And Uses ThereofDec 19, 2024 · Application 18743045Pending
- Chimeric Receptors And Methods Of Use ThereofAug 22, 2024 · Application 18501925Pending
- Armed Chimeric Receptors And Methods Of Use ThereofAug 22, 2024 · Application 18541684Pending
- Chimeric Receptors And Methods Of Use ThereofJun 11, 2024 · US 12,005,081Granted
- Drug-regulatable Transcription FactorsJun 6, 2024 · Application 18489693Pending
- Chimeric Receptors And Methods Of Use ThereofMay 30, 2024 · Application 18504037Pending
- ERT2 Mutants And Uses ThereofMay 9, 2024 · Application 18481805Pending
- Drug-regulatable Transcriptional RepressorsMay 2, 2024 · Application 18482513Pending
- ERT2 Mutants And Uses ThereofApr 25, 2024 · Application 18377191Pending
- Secretable Payload RegulationMar 21, 2024 · Application 18352079Pending
- Chimeric Antigen Receptors And Methods Of UseFeb 22, 2024 · Application 18501604Pending
- Chimeric Receptors And Methods Of Use ThereofFeb 8, 2024 · Application 18201596Pending
- Inducible Cell Death SystemsDec 21, 2023 · Application 18199154Pending
- Combinatorial Cancer ImmunotherapyAug 31, 2023 · Application 17872827Pending
- Inhibitory Chimeric Receptor ArchitecturesAug 31, 2023 · Application 17820804Pending
- Method And Compositions For Regulated Armoring Of CellsJan 12, 2023 · Application 17838118Pending
- Chimeric Receptor SensorsDec 15, 2022 · Application 17771289Pending
- Combinatorial Cancer ImmunotherapyDec 1, 2022 · Application 17848320Pending
- Combinatorial Cancer ImmunotherapySep 20, 2022 · US 11,446,332Granted
- Chimeric Inhibitory ReceptorSep 15, 2022 · Application 17636301Pending
- Combinatorial Cancer ImmunotherapyAug 23, 2022 · US 11,419,898Granted
- Fusion Constructs for Controlling Protein FunctionMar 24, 2022 · Application 17425609Pending
- Combinatorial Cancer ImmunotherapyMay 4, 2021 · US 10,993,967Granted
- Immunomodulating Cell CircuitsMar 19, 2020 · Application 16494482Pending
- Spatiotemporal RegulatorsAug 1, 2019 · Application 16319791Pending
- Genetic ErasersJun 6, 2019 · Application 16319786Pending
- Modified Degron Polypeptides And Uses ThereofApplication 19475651Pending
Related companies, and why
- OMICSCRAFT LLCSimilar federal contract value in Biotech · $2.7M in contracts
- RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLCSimilar federal contract value in Biotech · $2.6M in contracts
- Senti Biosciences Holdings, Inc.Similar federal contract value in Biotech · $2.6M in contracts
- TECHULON, INC.Similar federal contract value in Biotech · $2.5M in contracts
- REACTION BIOLOGY CORPORATIONSimilar federal contract value in Biotech · $2.5M in contracts
- PROTEIOS TECHNOLOGY, INC.Similar federal contract value in Biotech · $2.5M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .